The Portal of Geriatrics Online Education

The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines.

Pubmed ID: 
30154172
Abstract: 

Interest in the therapeutic potential of faecal microbiota transplant (FMT) has been increasing globally in recent years, particularly as a result of randomised studies in which it has been used as an intervention. The main focus of these studies has been the treatment of recurrent or refractory Clostridium difficile infection (CDI), but there is also an emerging evidence base regarding potential applications in non-CDI settings. The key clinical stakeholders for the provision and governance of FMT services in the UK have tended to be in two major specialty areas: gastroenterology and microbiology/infectious diseases. While the National Institute for Health and Care Excellence (NICE) guidance (2014) for use of FMT for recurrent or refractory CDI has become accepted in the UK, clear evidence-based UK guidelines for FMT have been lacking. This resulted in discussions between the British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS), and a joint BSG/HIS FMT working group was established. This guideline document is the culmination of that joint dialogue.

Date published: 
Thu, 11/01/2018
Journal: 
Gut
Author: 
Mullish BH
Quraishi MN
Segal JP
McCune VL
Baxter M
Marsden GL
Moore DJ
Colville A
Bhala N
Iqbal TH
Settle C
Kontkowski G
Hart AL
Hawkey PM
Goldenberg SD
Williams HRT
Source: 
Gut. 2018 Nov;67(11):1920-1941. doi: 10.1136/gutjnl-2018-316818. Epub 2018 Aug
Stellar: 
Stellar
Error | POGOe - Portal of Geriatrics Online Education

Error

The website encountered an unexpected error. Please try again later.